Walleye Trading
LCTX icon

Walleye Trading’s Lineage Cell Therapeutics LCTX Stock Holding History

Walleye Trading’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,572
Closed -$14K – 4741
2017
Q1 		$14K Buy
+4,572
New +$13K ﹤0.01% 4245

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Walleye Trading's LCTX Position: Q2 2017 in Review

Walleye Trading sold out of Lineage Cell Therapeutics (LCTX) in Q2 2017, closing a stake of 4,572 shares — an estimated $14K sold.

Walleye Trading first reported a position in LCTX in Q1 2017 and held it in 1 quarter. The position peaked at $14K in Q1 2017. 109 funds tracked by Wall St. Rank hold LCTX as of Q2 2017.

  • Walleye Trading reported no remaining Lineage Cell Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Walleye Trading sold 4,572 Lineage Cell Therapeutics shares in Q2 2017, an estimated $14K.
  • Walleye Trading first reported a position in Lineage Cell Therapeutics in Q1 2017 and held it in 1 quarter.
  • Walleye Trading's Lineage Cell Therapeutics position peaked at $14K in Q1 2017.
  • 109 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2017.

Based on Walleye Trading's 13F filing for Q2 2017, filed 14 Aug 2017.